Advertisement
Published in:
01-02-2015 | Brief Communication
Plasminogen activator entrapped within injectable alumina: a novel approach to thrombolysis treatment
Published in: Journal of Sol-Gel Science and Technology | Issue 2/2015
Log inActivate our intelligent search to find suitable subject content or patents.
Select sections of text to find matching patents with Artificial Intelligence. powered by
Select sections of text to find additional relevant content using AI-assisted search. powered by
Abstract
A major obstacle in the development of new enzyme-based thrombolytic systems is their low stability and extremely short half-life (usually, less than 2–6 min of circulation half-life), which requires their administration in large doses to obtain therapeutic effects, and as a consequence, inevitably leads to a significant incidence of hemorrhagic complications. Here we point to a potential solution of this problem by developing a new family of injectable composites for thrombolysis: plasminogen activator entrapped within alumina, where alumina is a pertinent drug carrier developed to prolong activity in vivo and to reduce the total administered dose of the drug necessary for the treatment, and hence its side effects.